Working… Menu
Trial record 11 of 333 for:    prostate cancer AND MRI | ( Map: United States )

Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03180398
Recruitment Status : Recruiting
First Posted : June 8, 2017
Last Update Posted : August 13, 2019
Information provided by (Responsible Party):
Ning Wen, Ph.D., Henry Ford Health System

Brief Summary:
This is a pilot study of implement multi-parametric MR imaging for organ delineation and tumor response assessment of prostate cancer patients being treated with radiation therapy. The study aims to generate intraprostatic lesions maps based on imaging, perform the treatment planning to compute the highest feasible simultaneous boosting dose to intraprostatic lesion and characterize longitudinal changes in imaging characteristics.

Condition or disease Intervention/treatment Phase
Prostate Cancer Device: Multiparametric MRI Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of Using Multi-parametric Magnetic Resonance Imaging for Organ Delineation and Tumor Response Assessment of Prostate Cancer Patients Being Treated With Radiation Therapy
Actual Study Start Date : October 4, 2017
Estimated Primary Completion Date : December 30, 2020
Estimated Study Completion Date : December 30, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Multi-parametric MRI for Prostate Cancer
MRI will be acquired for prostate cancer patients undergoing radiation treatment.
Device: Multiparametric MRI
MRI will be acquired before, during and after radiation treatment to evaluate treatment response

Primary Outcome Measures :
  1. Detection of imaging biomarkers to localize the intraprostatic lesions and predict radiation treatment response [ Time Frame: 2 years ]
    Identify the radiomics features selected from multimodal MRI to distinguish the dominant lesions from the normal tissues within the prostate. Track the changes of these features with longitudinal MRI scans to identify its correlation with the local control.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Histologically confirmed prostate adenocarcinoma

Exclusion Criteria:

  • Patients with metal fragments or implanted devices such as pacemakers and aneurysm clips are not eligible for the study considering

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03180398

Layout table for location contacts
Contact: Ning Wen, PhD 313-913-1162
Contact: Branislava Janic, MD, PhD 313-874-1681

Layout table for location information
United States, Michigan
Henry Ford Health System Recruiting
Detroit, Michigan, United States, 48202
Contact: Ning Wen, PhD    313-916-1162   
Contact: Branislava Janic, MD, PhD    313-874-1681   
Sponsors and Collaborators
Henry Ford Health System

Layout table for additonal information
Responsible Party: Ning Wen, Ph.D., Clinical Director, Physics Division, Henry Ford Health System Identifier: NCT03180398     History of Changes
Other Study ID Numbers: Prostate Imaging 10911
First Posted: June 8, 2017    Key Record Dates
Last Update Posted: August 13, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases